Advertisement
Australia markets close in 56 minutes
  • ALL ORDS

    8,080.60
    -37.70 (-0.46%)
     
  • ASX 200

    7,808.60
    -39.50 (-0.50%)
     
  • AUD/USD

    0.6629
    +0.0008 (+0.11%)
     
  • OIL

    77.04
    -0.53 (-0.68%)
     
  • GOLD

    2,373.20
    -19.70 (-0.82%)
     
  • Bitcoin AUD

    104,758.94
    -409.54 (-0.39%)
     
  • CMC Crypto 200

    1,515.17
    -11.25 (-0.74%)
     
  • AUD/EUR

    0.6120
    +0.0010 (+0.17%)
     
  • AUD/NZD

    1.0832
    -0.0026 (-0.24%)
     
  • NZX 50

    11,773.75
    +41.47 (+0.35%)
     
  • NASDAQ

    18,705.20
    -8.59 (-0.05%)
     
  • FTSE

    8,370.33
    -46.12 (-0.55%)
     
  • Dow Jones

    39,671.04
    -201.95 (-0.51%)
     
  • DAX

    18,680.20
    -46.56 (-0.25%)
     
  • Hang Seng

    18,914.18
    -281.42 (-1.47%)
     
  • NIKKEI 225

    39,085.92
    +468.82 (+1.21%)
     

Benitec Biopharma to Participate in the Citizens JMP Life Science Conference

Benitec Biopharma Inc.
Benitec Biopharma Inc.

HAYWARD, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference ("ddRNAi") platform, today announced that members of Benitec management will participate in Citizens JMP Life Science Conference, taking place in New York, NY from May 13-14, 2024.

Presentation Details:
Date: May 13, 2024
Time: 11:00 am EDT
Presenter: Jerel Banks, MD, PhD, Executive Chairman and Chief Executive Officer

The Benitec presentation will also be available via live webcast here.

ADVERTISEMENT

Please contact your Citizens JMP representative to schedule a 1x1 meeting with Benitec management.

About Benitec Biopharma Inc.

Benitec Biopharma Inc. (“Benitec” or the “Company”) is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines with headquarters in Hayward, California. The proprietary “Silence and Replace” DNA-directed RNA interference platform combines RNA interference, or RNAi, with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The Company is developing Silence and Replace-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD). A comprehensive overview of the Company can be found on Benitec’s website at www.benitec.com.

Investor Relations Contact:

Irina Koffler
LifeSci Advisors
Tel: (917) 734-7387
ikoffler@lifesciadvisors.com